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Abstract
Background: Subcutaneous Immunotherapy (SCIT) modifies the allergic response and relieves allergic symptoms.
SCIT is the only and a very effective treatment for insect venom allergy. We hypothesized that basophil sensitivity,
measured through the basophil activation test, would decrease during SCIT up dosing. Expression of CD203c was
compared to CD63 as marker for basophil activation, using a Bland Altman plot and ROC curves.
Methods: Patients (n = 18) starting subcutaneous SCIT for wasp allergy with an up dosing scheme of 7 to 11
weeks were enrolled. Heparinised blood samples were drawn at weeks 1-4, 7 and at the first maintenance visit.
Basophils were stimulated at 7 log dilutions of V. vespula allergen for 15 min, and were stained with CD203c and
CD63. Basophils were identified as CD203c
+ leukocytes, and the proportion of CD63
+ and CD203c
+ cells were
plotted against allergen concentration. A sigmoid curve was fitted to the points, and the allergen concentration at
which half of the maximal activation was achieved, LC50, was calculated. In another series of experiments, LC50
calculated in whole blood (AP) was subtracted from LC50 calculated with basophils suspended in plasma from a
nonatopic donor (HS) to determine the protective effect of soluble factors in blood of patients treated with SCIT.
Results: Heparin blood basophil activation was similar through CD63 and CD203c. Basophils were significantly
more sensitized three weeks after initiation of SCIT compared to baseline (p < 0,01). The difference in LC50
increased by 1,04 LC50 units (p = 0,04) in patients that had just achieved maintenance dose compared with
patients before initiating SCIT. When maintenance allergen concentrations had been reached, an increase in the
protective plasma component was documented. Blood basophil concentration was marginally reduced by SCIT.
Conclusion: Basophil activation is a versatile and sensitive tool that measures changes in the humoral immune
response to allergen during SCIT.
Introduction
Allergy to insect venom can be life threatening, and
leaves patients in a continuous state of anxiety [1]. Sub-
cutaneous immunotherapy (SCIT) is able to modify the
course of allergic disease, and is the only form of pro-
tection available against this allergy [2]. The efficacy of
SCIT for venom allergy has been documented in a meta
analysis [3]. SCIT induces cellular increase in IL-10 [4]
and changes in the humeral immune system; a transient
increase in free allergen specific immunoglobulin IgX
(mainly, but not exclusively IgG4 and IgA) and a
decrease in the ratio of free allergen specific immuno-
globulin to allergen specific IgE bound to effector cells
(mast cells and basophil granulocytes) [4,5].
The basophil activation test (BAT) is an increasingly
attractive method of assessing a type I allergic response
[6]. BAT has been used to measure effects of SCIT [7-9].
Although it may also have diagnostic potential, its real
power emerges when it is used to determine basophil
sensitivity with serial dilutions of allergen, where it corre-
lates well with clinical symptom strength [5,10]. The
optimal choice of activation marker has been a recurrent
theme; CD63 has historical value [11], and CD203c has
potential because it could be used for identification and
as activation marker at the same time [12]. In addition to
the blood basophils’ attractiveness as surrogate marker
for mast cell responses, it is a leukocyte that is recruited
from blood to inflamed tissue in a type I allergic response
[13,14]. Changes in blood basophil concentration during
allergen provocation may be a useful objective marker for
a type I allergic response [14].
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sensitivity, and hypothesised that we could use it to
measure changes in basophil sensitivity and soluble
Immunoglobulin induced in plasma by SCIT during the
up dosing phase of SCIT for wasp venom.
Methods
Patients
T h ee t h i c sc o m m i t t e eo fA a r h u sC o u n t ya p p r o v e da
project, in which patients aged 18 or older, registered to
begin subcutaneous immunotherapy with Vespula Alu-
tard (ALK-Abelló, Hørsholm, Denmark) were recruited.
From January to April 2007, 20 patients were recruited
and 18 patients completed the project (median age 54
years, interquartile range (IQR) 44-61 years, 8 women,
10 men). The clinical history of wasp allergy was con-
firmed by skin prick test (SPT) (ALK Abelló, Hørsholm,
Denmark) and by measuring specific IgE with the CAP
system (Phadia, Copenhagen, Denmark), with a thresh-
old of 0,35 kU/L. A SPT of >3 mm was considered posi-
tive. The median concentration of specific IgE to
vespula venom was 3,01 kU/L, with an IQR of 1,53 - 7
kU/L. Some of the patients (n = 5) were also sensitized
t ob e ev e n o mw i t ham e d i a na n dr a n g eo f0 , 9 5k U / L ,
ranging from 0,88 - 1,23 kU/L. One patient was negative
for both wasp and bee venom in the CAP test, but had a
positive prick test for wasp. In SCIT increasing doses of
an allergen, the patient is sensitized to, is injected
subcutaneously once a week until a maintenance dose
(prescheduled 100.000 SQU) is reached. Treatment con-
tinues for 3-5 years with injections every 6
th -8
th weeks.
Allergen injections, in the up dosing phase, can be
administered as clusters (11 injections at 7 visits) [15] or
after the conventional regime with one injection at each
visit (16 injections at 16 visits), if there is an increased
risk of adverse effects to the treatment. It is possible to
shift from the cluster up dosing regimen to the conven-
tional. Six of the 16 patients that started on our cluster
regimen completed it (Table 1). The remaining ten
patients transferred to the conventional regimen, on
which four patients had started. For generation of the
ROC curve, additional patients (3 women, 3 men) with
allergy to wasp venom (specific IgE > 0,35 kU/L), and
healthy, stung controls (5 women, 4 men) that did not
have specific IgE to wasp venom, were recruited. For
determination of differences in LC50 (log10 of the aller-
gen concentration resulting in 50% activation of baso-
phils) as the protective component in patient plasma
(see below) at maintenance dose, additional patients
receiving maintenance dose of SCIT for wasp venom
allergy (n = 3) or birch pollen allergy (n = 5) were
recruited (3 women, 5 men).
Basophil activation
For basophil activation, 4 ml venous blood was drawn
into heparin tubes before allergen injection at visits 1, 2,
Table 1 Selected salient clinical data for each patient
Pt nr Treatment Side effects maintenance dose Ratio CD63 activation at 0,1/1
1 Traditional fatigue 40000 1,07
2 traditional weals 100000 1,05
3 traditional weals 100000 0,82
4 traditional weals, fatigue 100000 0,87
5 traditional, discontinued heartbeat, nervousness (20) 0,78
6 cluster, discontinued itchy tongue (1000) 0,78
7 cluster hyperventilation 100000 0,65
8 cluster none 100000 0,95
9 cluster none 100000 0,66
10 cluster weals, itch, fatigue 100000 0,91
11 cluster weals 100000 0,87
12 cluster none 100000 0,71
13 cluster weals 60000 0,51
14 cluster weals 100000 1,22
15 cluster weals, fatigue 100000 1,00
16 change weals, oedema 100000 0,66
17 change weals, fatigue 100000 0,59
18 change weals 100000 2,09
19 change weals 100000 1,36
20 change weals 100000 1,13
Side effects, maintenance dose and CD63 activation at 0,1 ug/ml venom/1 ug/ml venom are listed against SCIT regimen (traditional 16 week up-dosing protocol/
7 week cluster up dosing protocol/change from 7 week to 16 week protocol) applied. Where the ratio of activation exceeds 0,95 it has been shown to be
predictive of side effects [7] and is printed bold. Side effects were weals around the site of injection
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was injected. Basophil activation was done as previously
described [6]; log dilutions of allergen (freeze-dried V.
vespula allergen, a gift from ALK-Abello, Hørsholm,
DK) ranging from 10 ug/ml final concentration to 10
pg/ml final concentration were compared with PBS only
as control. Heparinised blood (100 ul) was added within
2 hours of venesection, and incubated with allergen at
37°C for 20 minutes. A dilution series of anti FceRI anti-
body CRA1 (Catalog Nr 334602, Biolegend, CA) was
used as positive control (data not shown). Titrated
amounts of CD63 FITC (5 ul, Invitrogen MHCD6301)
and CD203c PE (5 ul, Beckmann-Coulter, IM3575) were
added for the last 5 minutes. Activation was terminated
by addition of 2 ml cold Saponin solution (0,15 mg/ml)
in PBS for exactly 2 minutes, followed by 0,25 ml of 5%
Methanol and 10% Paraformaledhyde in PBS and centri-
fugation at 400 g for 8 minutes at 4°C. Samples were
washed once with PBS, suspended in PBS and 150 000
events were acquired on a FACS Calibur flow cytometer
within 3 hours. On each day, compensation controls
were acquired for CD63 FITC and CD203c PE with
comp beads (Beckton-Dickinson, San Jose, CA). Data
was compensated and in the analysis, the FS:SS region
containing basophils was identified by back gating on
CD203c
+ cells (figure 1). A threshold set at 2% positive
cells in the PBS tube was used to determine percent
activated cells in the tubes incubated with allergen. The
fraction of positive cells is plotted against allergen
concentration.
The protective effect of plasma on basophil activation
was calculated as difference in LC50 in full blood (auto-
logous plasma) and LC50 of basophils in washed blood.
Washed blood was prepared by diluting 4 ml blood with
46 ml PBS, centrifuging and diluting again with PBS up
to 50 ml. The remaining cells were suspended in hetero-
logous plasma (1 ml) from a nonatopic donor for 15
min. Washed blood was used in a BAT test as described
above. In a control experiment, the LC50 of washed
blood was reconstituted with autologous plasma was
similar to that of whole blood (n = 5).
LC50 was calculated in R [16] by fitting a sigmoid
curve to data from each visit, and determining the
amount of allergen, that results in 50% of maximal
activation.
Generation of ROC curve
The allergen concentration at which sensitivity and spe-
cificity were optimal for CD63 and for CD203c was
determined with data from 24 clinically diagnosed wasp
allergic patients and 9 stung controls with no specific
IgE to vespula allergen, using plots of sensitivity and
Figure 1 Flow cytometric analysis of data of one representative patient. a-c; gating of a representative experiment. Black regions and
arrows indicate gating strategy. The PBS control is in blue, and the optimal allergen concentration (0,1 μg/ml) is in red. Histograms of expression
of CD63 at visit 2 (d). Data smoothed by R for CD63 were used to determine LC50, the allergen concentration at which half-maximal activation
(LC50) is achieved (e) LC50 was normalised to baseline and plotted against visit number.
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software [18]. For SCIT patients, baseline visits were
used for this analysis.
Bland Altman Analysis
The difference in basophil activation as measured by up-
regulation of CD63 and CD203c was investigated by a
Bland Altman analysis [19].
Blood basophil concentrations determined by constant
volume acquisition (CVA)
Blood basophil concentration was determined by CVA
[20]. Data is acquired for a constant, calibrated time,
which appears to give a more precise measurement of
volume than measurement with micro beads [20].
Briefly, 50 ul of blood was labelled with Lin1 FITC (BD
Catalog Nr 340546), CD123 PE (BD Catalog Nr
340545), CD45 PE Cy7 (BD Catalog Nr 555484) and
HLA DR APC (BD Catalog Nr 559866) for 15 min at
room temp, and lysed with FACS Lyse (BD Catalog Nr
349202). Data was acquired for 4 minutes from all
patients at all visits. Each day data was acquired, com-
pensation controls were acquired, and data was compen-
sated before analysis. Leukocytes were identified on a
CD45 vs. SS plot. Basophils were identified as CD45
dim
Lin1
neg CD123
bright HLA DR
neg cells, and the absolute
concentration was calculated.
Results
Increase in basophil sensitivity during the up dosing
phase of SCIT may be limited by factors in plasma
The effect of the up-dosing phase of subcutaneous
immunotherapy on basophil up regulation of CD63 and
CD203c (figure 1) was evaluated by fitting a sigmoid
curve to data points obtained with a 7-step logarithmic
dilution series of V. vespula allergen and blood of wasp
allergic patients drawn at each of visits 1, 2, 3, 4, 7 and
maintenance visit, if that did not coincide with visit 7.
From this curve at each visit, the concentration of aller-
gen resulting in half-maximal CD63 activation was
determined (figure 1e). It is termed LC50. When nor-
malised to the baseline visit, the LC50 was normally dis-
tributed. When plotted against visit, it increased
significantly from the first to the third week of immu-
notherapy (visit 1 - 3; p = 0, 0098, visit 2 - 3 p = 0,
0259, visit 3 - 4 p = 0, 0274, visit 3-maint p = 0, 0095
for all in a mixed linear model, p = 0,029 for CD63, p =
0,015 for CD203c, n = 18), and tended toward baseline
levels beyond that (figure 2a).
In a cross-sectional study to determine the contribu-
tion of humoral factors toward BAT performed in whole
blood, blood from different patients initiating SCIT and
patients on maintenance was washed with PBS and
replaced by heterologous serum (termed HS in contrast
to autologous plasma, AP) from a nonatopic donor as
described in methods, and was used in a BAT. Replacing
AP with HS dramatically increased basophil sensitivity.
At baseline the sensitivity increased by 2,576 LC50 units
(n = 8, p < 0,001), and at maintenance it increased by
3,595 LC50 units (n = 10, p < 0,001) (figure 2b). At the
early stage of maintenance, the reduction in basophil
sensitivity resulting from the autologous plasma had
thus increased by 1,02 LC50 units (p = 0,04) (figure 2c).
CD63 and CD203c are equivalent markers for basophil
activation
The optimal allergen concentration used to detect
allergy to V. vespula allergen was determined with sensi-
tivity vs. specificity curves and is illustrated with a ROC
curve (figure 3a) with 24 patients with documented
allergy and 9 exposed controls. The optimal final V. ves-
pula allergen concentration was 0,1 μg/ml. The sensitiv-
ity and specificity were 88% and 78% for CD63 at 3,28%
basophil activation. For CD203c, the sensitivity and spe-
cificity were 88% and 89% at 3,85% basophil activation.
Agreement between activation measurements per-
formed with CD63 as the predicate method and CD203c
determined with a Bland Altman plot [19] (figure 3b).
T h em e d i a nd i f f e r e n c eo fC D 6 3-C D 2 0 3 cw a s- 1 , 2 % ,
IQR 23,5% to -28,6% (not normally distributed, n =
914).
Difference between CD63 and CD203c was deter-
mined with an approximate T test in a linear mixed
model. For all concentrations there was no significant
difference between CD63 and CD203c with all p-values
greater than 0,11. When autologous plasma is replaced
with heterologous serum, the value of CD63-CD203c
increased from 4, 2% (IQR -20, 3 - 31, 7) to 41, 7%
(IQR 8, 3 - 73, 5, n = 135. In the same linear mixed
model that takes account for repeated measures the
relative difference between activation through CD63 and
CD203c was larger after plasma was replaced with
serum (p = 0,0172). It increased significantly (n = 15, p
< 0, 05) at four of the six highest allergen concentra-
tions, suggesting that CD203c is up regulated less than
CD63 when autologous plasma is replaced by heterolo-
gous serum. This was not due to an increase in baseline
MFI for CD203c, as the baseline MFI for CD63 and
CD203c increased 1,92 and 1,83 fold, respectively, after
replacement of plasma with serum. This was not
significant.
The blood basophil concentration decreases marginally
during SCIT
Blood basophil concentration measured using CVA was
37 (IQR 28 - 55, n = 18) cells/μl in allergic patients
treated with SIT, and 35 (IQR 23 - 42, n = 6, p = 0, 06)
cells/μl in controls. It increased by median 1 (IQR -2 -
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allergen injections and by median 3 (IQR 2 - 5) cells/μl
(12%) per 30 minutes in control persons after correction
for time between sampling. The difference was signifi-
cant in patients and controls when measured over 90
and 120 minutes (p < 0, 04), but not when measured
over 30 minutes.
Discordance between anamnesis, sIgE, prick test and BAT
O nt h es c a l ep r o p o s e db yB r o w n[ 2 1 ] ,1 4p a t i e n t s
reported moderate symptoms and 4 patients reported
severe symptoms when stung. Seven patients had other
allergies (2 latex, 3 bee, 2 cat, 3 house dust mites, 1 per-
fume, 1 kiwi, 1 nuts, 1 apples) and other allergic disease
(3 asthma, 3 hay fever, 3 Urticaria).
For two patients the activity of the basophils for both
CD203c and CD63 was only just above the threshold
values (i.e. positive) at some of the visits. These two
patients had almost no symptoms/adverse effects to
treatment with SIT, but they had moderate symptoms
as response to wasp sting, specific IgE at 3,01 kU/L and
6,0 kU/L respectively and positive skin prick tests (SPT)
before the beginning of SIT. One patient had moderate
symptoms to wasp sting and positive skin prick test but
negative specific IgE against wasp before the beginning
of SIT. The BAT of this participant was positive at all
visits, and the patient had local reactions to the treat-
ment and a systemic reaction at visit 2.
Discussion
We have monitored changes in basophil sensitivity as
the logarithm of the concentration of allergen that elicits
a half-maximal response, and blood basophil concentra-
tion, during the up dosing phase of SIT. We have found
Figure 2 The effect of SCIT on basophil activity. (a) Median LC50 is plotted against visit for patients on SCIT (n = 18). At visit 3 basophils are
significantly more sensitive than at other visits. (b) The protective effect of plasma is illustrated by replacing plasma with serum from a non-
allergic donor. (c) The net protective effect measured as change in LC50 between basophils activated in autologous serum and in heterologous
plasma is larger in patients on maintenance dose (n = 9) than in patients initiating SCIT (n = 10).
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a f t e r3w e e k so fS I T .T h i si n c rease in sensitivity may
reflect competing amounts of immunoglobulin on baso-
phils (IgE) and free immunoglobulin in circulation (IgX,
all classes of immunoglobulin with affinity for haptens
on allergen). It coincides with the early decrease in
basophil histamine release and increase in free IgG4 and
IgA described recently [4].
During ultra rush procedures of SCIT with Japanese
cedar [9] or birch or cat [8], maximal expression of
CD203c as % activated cells on basophils [9] or MFI [8]
after cross linking with allergen decreased with time.
BAT could not predict results of a sting challenge at 0,1
or 1,0 ug venom [22]. In a 5-day rush up dosing regi-
men, BAT at suboptimal concentrations appeared ele-
vated after 5 days corresponding to the findings after 3
Figure 3 Comparison of CD63 and CD203c as readout. (a) the ROCs for CD63 and CD203c at the optimal concentration of allergen, 0,1 μg/
ml, were indistinguishable. (b) Bland Altman plot of CD63-CD203c. Stippled lines indicate 25
th and 75
th quartiles.
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of this had not been tested). Basophil activation was sig-
nificantly reduced after six months and after three years
[23]. SCIT for birch or grass allergy significantly
decreased CD-sens (analogous to LC50) tenfold [5],
where the present results did not show a significant
change. This may be because in the present experiment,
BAT was done during the first 7 weeks assuming that
all patients would complete up dosing by a semi rush
protocol. Only 10 of 20 patients completed the semi-
rush protocol. The protective component in plasma
(that corresponds to Allergen Binding Activity (ABA))
increased by 1,04 LC50 units. This corresponds well to
the tenfold change in ABA published recently [5].
Change in basophil activation measured as CD63 or
CD203c activation at 0,1 ug/ml allergen did not vary
significantly during the up dosing phase. A ratio of
CD63 activation at 0,1 ug/ml/1 ug/ml > 92% has pre-
viously been shown to associate with severe side effects
[7]. In this study, 8 patients had a ratio > 92%. This did
not associate with side effects (Table 1). In a study of
modified rush up dosing of insect venom, the ratio of
basophil activation at 0,1 ug/ml venom/1 ug/ml venom
above 92% at baseline predicted severe side effects dur-
ing up dosing [7]. In the present study, 8 of 18 patients
had a ratio of basophil activation predicting severe side
effects. Neither others [24] nor we could confirm the
usefulness of this ratio.
The up dosing scheme in the present study is much
slower, and associated with very few side effects. This
may explain that we do not find the decrease that was
observed in the other studies, and why there were no
side effects to associate with a high ratio of activation.
The ratio of cell bound IgE to total free immunoglobu-
lin may be the most significant effect parameter, which
determines whether a basophil activation test becomes
positive. The protective effect of SCIT in patient plasma
(which we assume contains immunoglobulins competing
for epitopes on allergen) had increased by >1 LC50 unit
when comparing patients at baseline with patients just
initiating maitenance therapy. Basophil activation has
been shown to correlate well with clinical measures
[10]. Our study did not extend long enough to demon-
strate an effect of treatment on basophil activation by
flow cytometry, which has been shown by others [5].
Inhibition of histamine release, the gold standard for
basophil activity, was significantly different from base-
line after 6 weeks of SCIT [4]. Whilst single concentra-
tion analyses of basophil activation may not be sufficient
to monitor effects of SCIT [22], we confirm here that
this can be done with logarithmic series of dilutions of
allergen.
CD-sens is the fist algorithm developed to measure
basophil sensitivity in a basophil activation test [25].
The allergen dose giving maximal activation is deter-
mined, and a line of regression is calculated through
that point and the activation rates at the two preceding
allergen concentrations. The half-maximal activation is
determined from this interpolated line. CD-sens [25]
was evaluated as a technique to calculate basophil sensi-
tivity, but was not found to be useful in our hands
because the allergen concentrations we used were too
low to obtain a maximal activation as most of the curves
we obtained were not bell shaped, and because our log
dilutions were too widely spaced to obtain accurate CD-
sens. LC50 considers more values than CD-sens, and
may be less subjective. The values obtained with LC50
were larger than those obtained with CD-sens.
The present data gave us an opportunity to determine
the optimal allergen concentration for diagnosing wasp
allergy with a ROC curve to be 0,1 ug/ml final concen-
tration in the reaction vessel with blood, which com-
pares well with 0,5 ug/ml [22] and 0,5 - 0,05 ug/ml [23]
final concentration of V vespula allergen in BAT pub-
lished by others. The ROC curves for CD63 and
CD203c and the threshold for positivity were almost
identical for CD63 and CD203c, suggesting that the two
markers measure similar aspects of basophil activation.
Although Boumiza has disputed this [26], it has since
been confirmed by a number of clinically oriented publi-
cations [24,27,28]. We have previously shown that
choice of fluorochome and lysis procedure had favoured
CD203c over CD63, illustrating the need to consider all
aspects of an experiment [6]. We have done the first
Bland Altman analysis of CD63 and CD203c to show
that in full blood there is no difference between the
markers, whereas there is significantly less up regulation
of CD203c than of CD63 on washed basophils. The
effect appears not to be due to increased baseline
expression of CD203c, as this was similar for both mar-
kers. Washing away plasma immunoglobulins increases
the sensitivity of the test significantly, but masks the
clinical relevance as the total response is compounded
from the free immunoglobulin absorption of allergen
and the cross linking of cell bound IgE.
The basophil numbers we obtained using CVA were
w i t h i nar e c e n t l yp u b l i s h e dr e f e r e n c ei n t e r v a l[ 2 9 ] .P r e -
viously, we had shown that ingestion of allergen resulted
in a 20% reduction of blood basophil concentration
compared with placebo [14]. Allergen injection, as a
negative control, resulted in a marginal reduction in
blood basophil numbers compared with controls.
Changes in blood basophil concentration may thus be a
marker for type I allergic response. As the difference in
blood concentration of basophils increased with time
from 30 min to 120 min, the optimal time frame for
measuring blood basophil concentration as marker for a
type I allergic reaction remains to be determined.
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is a recurrent problem in allergen diagnosis, and some
have suggested that basophil activation should be the
arbitrating test if anamnesis and specific IgE do not sup-
port the same conclusion [30]. We found a rate of dis-
cordance between patient history and in vitro diagnostic
tests (3 patients of 18 with discordance between patient
history and in vitro diagnostic tests) that was similar to
others [23,30]. The fact that basophil activation in full
blood correlates with clinical symptoms and does reflect
the response by cell-bound IgE in the context of com-
peting immunoglobulins argues that it may occupy a
special niche amongst diagnostic tests for allergy.
Conclusion
Basophil sensitivity through CD63 or Cd203c increases
comparably during the first weeks of specific immu-
notherapy, but can measure a protective element already
when maintenance dose is reached.
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